Groundbreaking Cancer Trial in Prince George Shows Promising Results

BC Cancer has initiated a groundbreaking clinical trial in Prince George, marking a significant advancement in the treatment of oligometastatic cancer. This world-first trial, funded by the BC Cancer Foundation, is evaluating the efficacy of a single, targeted dose of radiation therapy for patients diagnosed with this intermediate stage of cancer, which commonly affects the breast, prostate, and lungs.

Oligometastatic cancer typically spreads from the primary tumor to three to five sites in the body, often impacting the bones, lymph nodes, and other organs. The implications of this trial could dramatically alter treatment protocols, potentially reducing both the duration of treatment and the associated side effects for patients across British Columbia, particularly in northern regions.

Innovative Approach with Advanced Technology

Led by Dr. Rob Olson, executive medical director and radiation oncologist at BC Cancer – Prince George, the trial is currently underway at multiple sites, including locations in Vancouver and Kelowna, as well as internationally. Recent investigations spearheaded by Dr. Olson demonstrated that up to eight doses of Stereotactic Ablative Radiotherapy (SABR) could effectively treat oligometastatic cancer with fewer side effects compared to traditional radiation methods, and in some cases, even lead to complete remission.

The $2.2 million trial is supported by a fundraising campaign from the BC Cancer Foundation and generous contributions from local philanthropists Selen and Anita Alpay, who donated $500,000 to facilitate ongoing efforts. Dr. Olson emphasized the trial’s unique approach, stating, “Instead of giving simple rectangles at low doses for palliation, we’re able to shape the dose over the last couple of decades. We’re now testing higher doses because we can do it safely.”

This innovative treatment method aims to provide a more effective solution for patients, particularly those in remote areas who may struggle to access comprehensive cancer care. Dr. Olson highlighted the importance of minimizing travel burdens for patients, stating, “If we can do it in a single treatment, most of the world will be very excited to do it in a single treatment.”

Patient Success Stories and Future Implications

The first patient enrolled in the SIMPLIFY trial was Violet MacLean, a grandmother from Quesnel, who received treatment in May 2025 after battling Stage 4 breast cancer for nearly a decade. After participating in the trial to address a new lesion on her hip bone, MacLean reported significant health improvements and currently enjoys remission at the treated site. She shared, “With just one treatment, I was able to get back to my life quickly.”

Since MacLean’s involvement, the trial has expanded to include over 600 patients globally, with cancer centers in the United States, Ireland, and other countries expressing interest. Dr. Olson noted the trial’s potential to lower patient costs and broaden access to advanced treatments, stating, “This study is patient-centric and trying to be cost-effective — it’s trying to reduce the number of treatments.”

Despite the benefits, Dr. Olson acknowledged challenges in securing funding from medical device companies, as the trial’s approach may not align with their business interests. “We need community support, which is why the BC Cancer Foundation is funding this,” he explained. “We’re doing what we think is the right thing to do.”

Looking ahead, Dr. Olson expressed optimism that the outcomes of these trials will not only benefit patients worldwide but will also attract more researchers and oncologists to Prince George, enhancing the region’s healthcare landscape. “By leading these trials, we will recruit other radiation oncologists and researchers who then move to Prince George because of it,” he said. “It’s changing the culture and making it an attractive place for people to move.”

Results from this innovative trial are expected to emerge in the coming years, potentially transforming how oligometastatic cancer is treated and providing hope for many patients facing this challenging diagnosis.